CHANDLER, Ariz., Aug. 05, 2024 (GLOBE NEWSWIRE) -- The Artificial Intelligence (AI) boom and rapid expansion of cloud-based services are accelerating the need for data centers to be more powerful, efficient and highly reliable. To meet the growing market demands, Microchip Technology (NASDAQ:MCHP) has released the Flashtec® NVMe® 5016 Solid State Drive (SSD) controller. The 16-channel, PCIe® Gen 5 NVM Express® (NVMe) controller is designed to offer higher levels of bandwidth, security and flexibility. "Data ...

文章核心观点 - 布里奇尔航空集团控股公司(Bridger Aerospace Group Holdings, Inc.)是美国最大的航空消防公司之一 [1][5] - 公司将于2024年8月12日发布2024年第二季度财务业绩 [1][2] - 公司管理层将于2024年8月12日举行投资者电话会议,讨论业绩和业务前景 [2] - 公司还宣布将参加8月14日在波士顿举行的Canaccord Genuity年度增长大会和9月5日在纽约举行的Gabelli基金航空航天与国防年度研讨会 [4] 公司概况 - 布里奇尔航空集团控股公司总部位于蒙大拿州贝尔格莱德 [5] - 公司是美国最大的航空消防公司之一,为联邦和州政府机构(包括美国林业局)以及国际客户提供航空消防和野火管理服务 [5] 财务信息 - 公司将于2024年8月12日发布2024年第二季度财务业绩 [1] - 公司将于2024年8月12日举行投资者电话会议,讨论业绩和业务前景 [2] 投资者关系 - 公司宣布将参加8月14日在波士顿举行的Canaccord Genuity年度增长大会和9月5日在纽约举行的Gabelli基金航空航天与国防年度研讨会 [4] - 投资者可以通过公司网站的投资者关系页面观看相关网络直播 [4] - 公司提供了投资者关系联系人信息 [6]

TAMPA, FL and COMMACK, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. ("TRxADE") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of TRxADE, today announced the appointment of Narasimhan Mani, Ph.D., MBA as Scienture's President. Shankar Hariharan, Ph.D., the current President and CEO, will be CEO of Scienture. Rahul Surana, Ph.D., MBA has been promoted to Executive VP and COO of Scienture. Dr. Narasimhan Mani is an experienced healthcare professional and a proven leader ...

LAKEWOOD, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter ("1Q25") ended June 30, 2024 (amounts in thousands). First quarter FY 2025 compared to first quarter FY 2024: Revenues increased 14.9%Non-GAAP core organic revenues1 growth was 3.0%Operating income increased 940%Non-GAAP adjusted operating income excluding unus ...

ATHENS, GREECE, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Global Ship Lease, Inc. (NYSE:GSL) (the "Company", "Global Ship Lease" or "GSL"), an owner of containerships, announced today its unaudited results for the three and six month periods ended June 30, 2024. Second Quarter of 2024 and Year to Date Highlights - Reported operating revenue of $175.0 million for the second quarter of 2024, an increase of 8.0% on operating revenue of $162.1 million for the prior year period. For the six months ended June 30, 2024, o ...

Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with Programs Progressing in Myotonic Dystrophy Type-1 (DM1) and Huntington's Disease (HD) Cash and Securities of $261.0 Million Supports Operations Through Potentially Four Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious ...

ANDOVER, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. ("Byrna" or the "Company") (NASDAQ:BYRN), a technology company, specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today announced that its Board of Directors has approved a $10 million stock repurchase program. This program authorizes the Company to repurchase up to $10 million of its common stock over a twenty-four month period. "Based on our continuing strong operating perf ...

Net product revenue of $70.3 million in 2Q and $166.2 million since launch in August 2023 On track to deliver three clinical readouts in 2H 2024Jeune Aesthetics' KB301 Phase 1 PEARL-1 study (Cohorts 3 and 4) in 3Q 2024; KB408 Phase 1 SERPENTINE-1 study for the treatment of AATD in 4Q 2024; and KB707 Phase 1 OPAL-1 study for the treatment of injectable solid tumors in 4Q 2024 Strong balance sheet, ending the quarter with $628.9 million in cash and investments PITTSBURGH, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Kry ...

文章核心观点 - 公司TenX Keane Acquisition与Citius Oncology完成合并,新公司将在纳斯达克上市,名称为Citius Oncology, Inc. [3] - 合并有利于支持LYMPHIR的商业化(如获批)和探索其他肿瘤资产 [2][5] - 合并后Citius Pharma将持有Citius Oncology约90%的股份 [6] 公司概况 - TenX Keane Acquisition是一家特殊目的收购公司(SPAC) [9] - Citius Oncology将作为一个平台开发和商业化创新的靶向肿瘤疗法 [10] - Citius Oncology的主要资产是LYMPHIR,正在申请FDA批准用于治疗难治性或复发性皮肤T细胞淋巴瘤(CTCL) [10][12] - LYMPHIR是一种特殊设计的白细胞介素-2-白喉毒素融合蛋白,可直接杀死肿瘤细胞并增强机体免疫反应 [12] - LYMPHIR已获FDA孤儿药认定,并于2021年在日本获批用于治疗CTCL和外周T细胞淋巴瘤 [13] - Citius Pharma是一家专注于关键护理产品的后期生物制药公司,LYMPHIR是其主要资产 [14]

Aflac's Wellness Matters survey uncovers the prevalent use of urgent care and emergency rooms, barriers to preventive care, and vital aspects of health care for Hispanics and younger generationsCOLUMBUS, Ga., Aug. 5, 2024 /PRNewswire/ -- Many Hispanic Americans are not taking personal charge of their health journeys through preventive care, routine wellness checkups and important screenings that could help detect and support early treatment of serious illnesses. These are some of the findings from the secon ...